Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
Agency initiates safety label change and notifies physicians of possible link
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Importantly, the combination of giredestrant and everolimus was well tolerated
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
Subscribe To Our Newsletter & Stay Updated
